Sam Fitzpatrick just finished 18-months of grueling treatment sessions following a Stage IV bowel cancer diagnosis at the age of 33.

But he would tell you he’s lucky.

Bowel Cancer Australia today released initial findings from the first national My Colonoscopy Experience questionnaire. The questionnaire opened in September 2018 at the same time as the Colonoscopy Clinical Care Standard, created by the Australian Commission on Safety and Quality in Health Care (ACSQHC).

Australia's Therapeutic Goods Administration (TGA) has today given Keytruda® (pembrolizumab) provisional approval for patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) bowel cancer.

In the first week of Bowel Cancer Awareness Month 2019, the University of Sydney officially opened the Kolling Institute node of their Sydney Mass Spectrometry core facility. The facility was made possible with a significant financial gift of $500,000 from Bowel Cancer Australia, established to support the research of the Lawrence Penn Chair of Bowel Cancer Research, Professor Mark Molloy PhD and his research team. 

Of the 4.1 million people invited to participate in the National Bowel Cancer Screening Program between January 2016 and December 2017, only four in every ten took up the offer according to the latest AIHW report.

As an in-house Bowel Care Nurse at Bowel Cancer Australia, Fiona has dedicated the past eight years to the prevention, early diagnosis, research, quality treatment and the best care for everyone affected by bowel cancer.

A new global study of seven high-income countries has found that in the decade up to 2014, Australia’s second most deadly cancer is on the rise in people under 50.

Inflammatory bowel disease (IBD) describes disorders that involve chronic inflammation of the digestive tract.

Chronic inflammation can cause continuous turnover of cells in the intestinal lining.

“Imagine a roller coaster,” said Dr Peter Harvey, Consultant Clinical Psychologist at Leeds Teaching Hospitals Trust in a presentation he gave titled ‘After the Treatment Finishes – Then What?’